As the analysis of serum C-C motif chemokine ligand 20 (CCL20) is not standard in clinical practice, and, therefore, no reference range exists, we determined the median CCL20 levels of the 101 advanced melanoma patients at baseline prior to the initiation of immunotherapy. Here, CCL20 is linked to melanoma.